688235 BeiGene, Ltd.
- 182.18
- +3.68+2.06%
BeiGene, Ltd. News
BofA Securities Maintains BeiGene(ONC.US) With Hold Rating, Maintains Target Price $207
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260
BeiGene (BGNE) Gets a Buy From TD Cowen
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $286
Morgan Stanley Reaffirms Their Buy Rating on BeiGene (BGNE)
BeiGene Analyst Ratings
Morgan Stanley Assumes BeiGene at Overweight, Announces Price Target of $300
Bernstein Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
BeiGene Is Maintained at Buy by TD Cowen
BeiGene Analyst Ratings
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $260
No Data
